RNS Number:1654L
Hikma Pharmaceuticals Plc
27 October 2006



                            Section 198 Notification


London, 27 October 2006 - On 27 October 2006, Hikma Pharmaceuticals PLC (LSE:
HIK) (DIFX: HIK) ("the Company") received  notification from The Capital Group
Companies, Inc., pursuant to Section 198 Companies Act 1985, that at the close
of  its business on 25 October 2006, The Capital Group Companies, Inc., on
behalf of its affiliates, including Capital  Research and Management Company,
had an interest in 8,600,003 ordinary shares of 10p each in the Company, which 
represents 5.129 per cent of the issued ordinary share capital of the Company,
as follows:

                      No. of shares                  Percent of 
                                                     ordinary shares 
                                                     outstanding
The Capital Group

Companies, Inc.           8,600,003                  5.129%
held as follows:

Capital Research and
Management Company        8,600,003                  5.129%
of which:

SMALLCAP World Fund       5,069,153                  3.023%


Registered holders:

State Street Nominees Limited                        5,069,153
Chase Nominees Limited                               3,530,850

                                      Total          8,600,003



                                    - ENDS -



Enquiries:

Hikma Pharmaceuticals PLC                               +44 20 7399 2670
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director

Brunswick Group LLP                                     +44 20 7404 5959
Jon Coles / Justine McIlroy / Alex Tweed




Notes to Editors


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ("MENA") region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
HOLILFSSIELDFIR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.